SubHero Banner

Tasigna® (nilotinib) – Expanded indication

September 23, 2021 - The FDA approved Novartis’ Tasigna (nilotinib), for the treatment of pediatric patients greater than or equal to 1 year of age with chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy.

Download PDF